Geothermal Developer Ignis H2 Energy Raises $12.5M in Series A First Close
19.2.2025 13:47:00 CET | Business Wire | Press release
Funds to Advance Exploration Projects in USA, Turkey, Indonesia & Italy
Ignis H2 Energy Inc. (“Ignis Energy”), a geothermal exploration and development startup, announced today the successful first closing of its Series A funding round, securing $12.5 million from a consortium of investors, including leading funds and private individuals. The funding round was led by alfa8 and includes a commitment from drilling contractor Nabors Industries, alongside investments from existing shareholders, private individuals, and family offices.
Advancing a Global, Risk-Balanced Geothermal Portfolio
Unlike other startups in the geothermal industry, Ignis Energy does not rely on a single technology or opportunity. Instead, it manages a risk-balanced portfolio of geothermal power-producing opportunities across high-enthalpy environments worldwide. By leveraging proven technologies and insights from a distinguished panel of geothermal experts, Ignis Energy diversifies risk while ensuring a steady pipeline of sustainable energy projects. The company has already secured promising geothermal opportunities in Turkey, Alaska, California, Nevada, and Italy.
Driven by a mission to provide affordable, reliable, and sustainable baseload geothermal energy, Ignis Energy integrates extensive expertise from the oil and gas sector into geothermal exploration and development. The company is pioneering the use of cutting-edge machine learning models to predict, locate, and explore geothermal resources more efficiently, leading to better drilling outcomes and lower project risk. With a portfolio spanning multiple geographies and geological formations, Ignis Energy is targeting the development of one gigawatt of documented producible geothermal reserves by 2030.
Strategic Investors Committed to Geothermal Innovation
Alfa8: Investing in a Sustainable Future -- alfa8 is committed to advancing technologies that accelerate the global shift toward sustainable energy solutions. With a strong focus on geothermal innovation and next-generation renewables, the firm backs forward-thinking pioneers redefining the energy landscape while ensuring environmental stewardship. Erin Glenn, COO of alfa8, emphasized the firm’s strategic approach: “As a patient capital investor, alfa8 is dedicated to funding transformative ventures that address the energy crisis, drive the adoption of geothermal energy, and push the frontiers of maritime decarbonization and critical sustainability initiatives.”
Nabors Industries: Driving the Future of Geothermal Exploration -- With a presence in over 20 countries, Nabors Industries is a leading provider of advanced technology for the energy industry. By leveraging its core competencies, particularly in drilling, engineering, automation, data science and manufacturing, Nabors aims to innovate the future of energy and enable the transition to a lower carbon world. Spearheading advancements in geothermal technologies and projects is a key focus of Nabors’ energy transition strategy.
Guillermo Sierra, VP, Strategic Initiatives at Nabors, asserted that “Ignis Energy will be a strong addition to our geothermal investment portfolio as we seek to catalyze breakthrough technologies and collaborate with experienced operators to deliver energy without compromise. We believe Ignis’ project portfolio and management team is best-in-class and we are pleased to collaborate with them on near-term projects and support their long-term growth, which we expect will include additional collaboration with Nabors’ other geothermal technology ventures.”
Richard Calleri, CEO of Ignis Energy stated “we are a geothermal exploration and development company focused on building a risk-balanced portfolio of geothermal power plants across key global markets. By combining proven technologies, expert knowledge, and advanced data analytics, Ignis Energy is unlocking the full potential of geothermal resources and accelerating the transition to a cleaner, more sustainable energy future.”
Marcus Oesterberg, COO of Ignis Energy added that “our approach is technology agnostic with a focus on high enthalpy and predominantly traditional geothermal resources that can be developed with today’s technology for power production.”
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219707620/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom